Search Results for "f"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for f. Results 831 to 840 of 862 total matches.

A New Sunscreen Agent

   
The Medical Letter on Drugs and Therapeutics • May 20, 2007  (Issue 1261)
, Copenhagen Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D ...
Ecamsule (terephthalylidene dicamphor sulfonic acid), the first new sunscreen agent to be approved by the FDA in 18 years, is now available in the US in a moisturizer called Anthelios SX. Ecamsule has been used in Canada and Europe for more than 10 years.
Med Lett Drugs Ther. 2007 May 20;49(1261):41-3 |  Show IntroductionHide Introduction

Drugs for Percutaneous Coronary Interventions

   
The Medical Letter on Drugs and Therapeutics • Dec 06, 2004  (Issue 1197)
., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D ...
Percutaneous coronary intervention (PCI), such as balloon angioplasty or stent placement, predisposes to subsequent thrombosis. The current pharmacologic approach to prevention of this problem combines an anticoagulant with one or more antiplatelet drugs.
Med Lett Drugs Ther. 2004 Dec 6;46(1197):100 |  Show IntroductionHide Introduction

Clopidogrel (Plavix) Revisited

   
The Medical Letter on Drugs and Therapeutics • Apr 10, 2006  (Issue 1232)
, M.D., University Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt School of Medicine F. Estelle ...
Clopidogrel (Plavix - Sanofi-Aventis and Bristol-Myers Squibb), an oral thienopyridine that inhibits platelet aggregation, is now being advertised directly to the public on television. Clopidogrel is approved by the FDA for secondary prevention of myocardial infarction (MI), stroke and other vascular events and for use in patients with acute coronary syndrome (unstable angina or non-ST-elevation MI), including those undergoing angioplasty. It is used off-label for patients with ST-elevation acute MI
Med Lett Drugs Ther. 2006 Apr 10;48(1232):29-31 |  Show IntroductionHide Introduction

Aliskiren (Tekturna) for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Apr 09, 2007  (Issue 1258)
., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H ...
Aliskiren (ah LIS ker in; Tekturna - Novartis), the first direct renin inhibitor, has been approved by the FDA for treatment of hypertension. It is indicated for oral use either as monotherapy or in combination with other antihypertensive agents.
Med Lett Drugs Ther. 2007 Apr 9;49(1258):29-31 |  Show IntroductionHide Introduction

Drugs for Psoriatic Arthritis

   
The Medical Letter on Drugs and Therapeutics • Dec 30, 2019  (Issue 1588)
concentrations of tofacitinib; concurrent use requires a reduction 1. F Alinaghi et al. Prevalence of psoriatic ...
Psoriatic arthritis is a chronic inflammatory arthropathy associated with psoriasis. A recent review found that about 20% of patients with psoriasis have psoriatic arthritis. Updated guidelines for treatment of psoriatic arthritis have recently been published.
Med Lett Drugs Ther. 2019 Dec 30;61(1588):203-10 |  Show IntroductionHide Introduction

Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection

   
The Medical Letter on Drugs and Therapeutics • Oct 09, 2017  (Issue 1531)
, 2017. 2. F Poordad et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 ...
The FDA has approved Mavyret (Abbvie) and Vosevi (Gilead), two new fixed-dose combinations of direct-acting antiviral (DAA) drugs, for treatment of chronic hepatitis C virus (HCV) infection caused by any of the six major HCV genotypes in patients without cirrhosis or with compensated cirrhosis. Both are approved for use in treatment-experienced patients. Mavyret is also approved for treatment-naive patients.
Med Lett Drugs Ther. 2017 Oct 9;59(1531):166-70 |  Show IntroductionHide Introduction

OTC Drugs for Seasonal Allergies

   
The Medical Letter on Drugs and Therapeutics • Apr 22, 2019  (Issue 1570)
of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2005; 95:272. 13. F Etwel et al. The risk ...
Patients with seasonal allergies often experience nasal itching and congestion, sneezing, rhinorrhea, and itchy, watery eyes. Oral, intranasal, and ophthalmic preparations are widely available over the counter (OTC) for relief of symptoms. Prescription products for management of allergic rhinitis and allergic conjunctivitis are reviewed separately.
Med Lett Drugs Ther. 2019 Apr 22;61(1570):57-60 |  Show IntroductionHide Introduction

Drugs for Parasitic Infections

   
Treatment Guidelines from The Medical Letter • Aug 01, 2013  (Issue 143)
With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by parasites. The table in this document lists first-choice and alternative drugs for most parasitic infections.
Treat Guidel Med Lett. 2013 Aug;11(143):e1-15 |  Show IntroductionHide Introduction

Antiviral Drugs for Varicella-Zoster Virus and Herpes Simplex Virus Infections

   
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018  (Issue 1556)
. Management of herpes in pregnancy. Obstet Gynecol 2007; 109:1489. 10. F Sahoo et al. Herpes zoster ...
The recommendations for treatment of varicella-zoster virus (VZV) and herpes simplex virus (HSV) infections are listed in tables 1 and 2. Vaccination against VZV was reviewed in a previous issue.
Med Lett Drugs Ther. 2018 Sep 24;60(1556):153-7 |  Show IntroductionHide Introduction

Treatment of Clostridioides difficile Infection

   
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021  (Issue 1632)
associated disease. Ann Surg 2011; 254:423. 15. F Lamontagne et al. Impact of emergency colectomy ...
Clostridioides (formerly Clostridium) difficile infection (CDI) is the most common infectious cause of healthcare-associated diarrhea in adults. Guidelines on management of CDI have recently been updated.
Med Lett Drugs Ther. 2021 Sep 6;63(1632):137-41 |  Show IntroductionHide Introduction